Novel Muscle Therapeutics Through Selective Beta-Adrenoceptor Signalling

Grant number: 1026231 | Funding period: 2012 - 2015

Completed

Abstract

Muscle wasting is an urgent and unmet health risk commonly associated with ageing; cancer, muscle diseases, and conditions including cardiovascular and metabolic disorders. Manipulating beta-adrenergic signalling is a therapeutic target for muscle wasting but treatments have so far been limited due to cardiaovascular side effects. Using cutting edge technologies, we will identify treatments that effectively separate beneficial effects on skeletal muscles from unwanted effects on the heart.

Related publications (2)

Using AAV vectors expressing the β 2 -adrenoceptor or associated Gα proteins to modulate skeletal muscle mass and muscle fibre size

A Hagg, TD Colgan, RE Thomson, H Qian, GS Lynch, P Gregorevic

2016-03-14

Anabolic β 2 -adrenoceptor (β 2 -AR) agonists have been proposed as therapeutics for treating muscle wasting but concerns regardin..

Functional β-adrenoceptors are important for early muscle regeneration in mice through effects on myoblast proliferation and differentiation

JE Church, J Trieu, R Sheorey, AYM Chee, T Naim, DM Baum, JG Ryall, P Gregorevic, GS Lynch

2014-07-07

Muscles can be injured in different ways and the trauma and subsequent loss of function and physical capacity can impact significa..

University of Melbourne Researchers

Gordon Lynch

Paul Gregorevic